CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week, highlighting reports from Amazon, Alphabet, Eli ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

The 1970s and early 1980s were challenging due to high inflation, stagflation ... by 150 percentage points (see more details here). Eli Lilly and Company (NYSE:LLY) develops and markets human ...

Stocks swiftly recovered from the DeepSeek-driven sell-off early in the week but came under pressure on Friday amid concerns ...

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals that distract from plans that would hit Americans -- like drug prices.